Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück zu finanzen.net geht es hier.
SMI 10’794 3.3%  SPI 13’946 3.4%  Dow 31’501 2.7%  DAX 13’118 1.6%  Euro 1.0116 0.0%  EStoxx50 3’533 2.8%  Gold 1’827 0.2%  Bitcoin 20’448 0.9%  Dollar 0.9593 -0.2%  Öl 113.2 3.1% 
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
20.05.2022 14:33:48

Press Release: Novartis Cosentyx(R) (secukinumab) -2-

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Thomas Hungerbuehler +41 61 324 8425 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

References

1. Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of

secukinumab 150 mg in ankylosing spondylitis: 5-year results from the

phase III MEASURE 1 extension study. RMD Open. 2019;5:e001005.

2. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates

high sustained efficacy and a favourable safety profile in patients with

moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE

Extension Study). J Eur Acad Dermatol Venereol. 2018;32:1507-1514.

3. Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained

Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final

5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol.

2020;2:18-25.

4. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human

anti-interleukin-17A monoclonal antibody, in patients with psoriatic

arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled,

phase 3 trial. Lancet. 2015;386:1137-46.

5. Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data.

Novartis Pharmaceuticals Corp; July 23, 2018.

6. Data on file. CAIN457F2310 and CAIN457F2305 summary of 5-year clinical

safety in (ankylosing spondylitis). Novartis Pharmaceuticals Corp; May

2019.

7. Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals

Corp; November 2008.

8. Novartis Europharm Limited. Cosentyx(R) (secukinumab): Summary of Product

Characteristics. Available from:

https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf [Last

accessed: May 2022].

9. Ruperto N, Foeldvari I, Alexeeva E, et al. Efficacy and Safety of

Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic

Arthritis: Primary Results from a Randomised, Double-blind,

Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA).

Presented as a late-breaking abstract at European Alliance of

Associations For Rheumatology (EULAR) Virtual Congress; June 2-5, 2021.

Abstract LB0004.

10. Brunner H, Foeldvari I, Alexeeva E, et al. Secukinumab Treatment In

Children And Adolescents with Enthesitis-Related Arthritis And Juvenile

Psoriatic Arthritis: Efficacy And Safety Results From A Phase 3 Study.

Presented at the American College of Rheumatology (ACR) Convergence;

October 28-30, 2021. Abstract 1424.

11. Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; December

2021.

12. American College of Rheumatology. Juvenile Arthritis [online] March 2019.

Available from:

https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Juvenile-Arthritis [Last

accessed: May 2022].

13. Momah T and Ray L. Juvenile idiopathic arthritis: Old disease, new

tactics. J Fam Pract. 2019;68:E8-E13.

14. Weiss PF, Beukelman T, Schanberg LE, et al. Enthesitis-related arthritis

is associated with higher pain intensity and poorer health status in

comparison with other categories of juvenile idiopathic arthritis: the

Childhood Arthritis and Rheumatology Research Alliance Registry. J

Rheumatol. 2012;39:2341-51.

15. Glerup M, Rypdal V, Arnstad ED, et al. Long-Term Outcomes in Juvenile

Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based

Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care Res

(Hoboken). 2020;72:507-516.

16. Clinical Trials.gov. Secukinumab Safety and Efficacy in Juvenile

Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA).

Available from: https://clinicaltrials.gov/ct2/show/NCT03031782. [Last

accessed: May 2022].

17. Cosentyx [Prescribing Information]. East Hanover, NJ: Novartis

Pharmaceuticals Corp; 2022.

18. Mix Online. Ministry of Health, Labor and Welfare approves additional

indications for 12 products, etc. Addition of Enrest's "hypertension"

[online]. September 28, 2021. Available from:

https://www.mixonline.jp/tabid55.html?artid=71852. [Last accessed May

2022].

19. Gov.br. Ministry of Health. Cosentyx (secukinumab): Extended Use

[online]. Available from:

https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/cosentyx-secuquinumabe-ampliacao-de-uso.

[Last accessed May 2022].

20. Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting

interleukin-17. Br J Dermatol. 2012;167:717-24.

21. McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for

treatment of active psoriatic arthritis (EXCEED): a double-blind,

parallel-group, randomised, active-controlled, phase 3b trial. Lancet.

2020;395:1496-1505.

22. Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals

Corp; December 2008.

(END) Dow Jones Newswires

May 20, 2022 08:34 ET (12:34 GMT)


BITCOIN KURSZIEL 100'000 US-DOLLAR? WELCHER COIN KÖNNTE DER NÄCHSTE VERDOPPLER SEIN?

Informieren Sie sich aus erster Hand über Nachrichten, die Krypto-Kurse bewegen. Abonnieren Sie jetzt kostenlos unseren neuen Krypto-Newsletter!